Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer

Authors: Aoife J Lowery, Karl J Sweeney, Alan P Molloy, Emer Hennessy, Catherine Curran, Michael J Kerin

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine produced physiologically by the uterus. Pathological secretion by tumours promotes growth and metastasis. High circulating VEGF levels potentially have a deleterious effect on breast cancer by promoting disease progression.
The aims of this study were to investigate circulating VEGF levels in breast cancer patients and assess the effect of menopause or hysterectomy on systemic VEGF.

Methods

Patients undergoing primary surgery for breast cancer and controls matched for age, menopausal and hysterectomy status were prospectively recruited. Serum VEGF, FSH, LH, estrogen, progesterone and platelet levels were measured. Serum VEGF was corrected for platelet load (sVEGFp) to provide a biologically relevant measurement of circulating VEGF. SVEGFp levels were analyzed with respect to tumor characteristics, menopausal status and hysterectomy status.

Results

Two hundred women were included in the study; 89 breast cancer patients and 111 controls. SVEGFp levels were significantly higher in breast cancer patients compared to controls (p = 0.0001), but were not associated with clinico-pathological tumor characteristics. Systemic VEGF levels reduced significantly in the breast cancer patients following tumor excision (p = 0.018). The highest systemic VEGF levels were observed in postmenopausal breast cancer patients. Postmenopausal women who had had a previous hysterectomy had significantly higher VEGF levels than those with an intact postmenopausal uterus (p = 0.001).

Conclusion

This study identifies an intact postmenopausal uterus as a potential means of reducing circulating levels of VEGF which could confer a protective effect against breast cancer metastatic potential.
Appendix
Available only for authorised users
Literature
1.
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9 (6): 669-76. 10.1038/nm0603-669.CrossRefPubMed
2.
Punyadeera C, Thijssen VL, Tchaikovski S, Kamps R, Delvoux B, Dunselman GA, de Goeij AF, Griffioen AW, Groothuis PG: Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. Mol Hum Reprod. 2006, 12 (6): 367-75. 10.1093/molehr/gal027.CrossRefPubMed
3.
Zaitseva M, Yue DS, Katzenellenbogen JA, Rogers PA, Gargett CE: Estrogen receptor-alpha agonists promote angiogenesis in human myometrial microvascular endothelial cells. J Soc Gynecol Investig. 2004, 11 (8): 529-35. 10.1016/j.jsgi.2004.06.004.CrossRefPubMed
4.
Heer K, Kumar H, Speirs V, Greenman J, Drew PJ, Fox JN, Carleton PJ, Monson JR, Kerin MJ: Vascular endothelial growth factor in premenopausal women – indicator of the best time for breast cancer surgery?. Br J Cancer. 1998, 78 (9): 1203-7.CrossRefPubMedPubMedCentral
5.
Kusumanto YH, Hospers GA, Sluiter WJ, Dam WA, Meijer C, Mulder NH: Circulating vascular endothelial growth factor during the normal menstrual cycle. Anticancer Res. 2004, 24 (6): 4237-41.PubMed
6.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993, 362: 841-44. 10.1038/362841a0.CrossRefPubMed
7.
Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ: Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res. 2001, 7 (11): 3491-4.PubMed
8.
Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, Diadema MR, Aurilio G, Santabarbara G, Ruggiero R, Belli C, Irlandese E, Fasano M, Ciardiello F, Procaccini E, Lo Schiavo F, Catalano G, De Vita F: Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Cancer Investigation. 2008, 26 (3): 250-5. 10.1080/07357900701560612.CrossRefPubMed
9.
Dabrosin C: Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res. 2005, 11 (22): 8036-41. 10.1158/1078-0432.CCR-05-0977.CrossRefPubMed
10.
Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Harkonen PL: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol. 1999, 149 (1–2): 29-40. 10.1016/S0303-7207(99)00003-9.CrossRefPubMed
11.
Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA. 2000, 97: 10972-7. 10.1073/pnas.200377097.CrossRefPubMedPubMedCentral
12.
Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M: Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res. 2002, 62 (17): 4977-84.PubMed
13.
Wu J, Richer J, Horwitz KB, Hyder SM: Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res. 2004, 64 (6): 2238-44. 10.1158/0008-5472.CAN-03-3044.CrossRefPubMed
14.
Ryden L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G: Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat. 2005, 89 (2): 135-43. 10.1007/s10549-004-1655-7.CrossRefPubMed
15.
Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG: Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer. 2003, 98 (10): 2125-32. 10.1002/cncr.11764.CrossRefPubMed
16.
Banerjee S, Pancholi S, A'Hern R, Ghazoui Z, Smith IE, Dowsett M, Martin LA: The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin Cancer Res. 2008, 14 (9): 2656-63. 10.1158/1078-0432.CCR-07-1352.CrossRefPubMed
17.
Fuckar D, Dekanic A, Stifter S, Mustac E, Krstulja M, Dobrila F, Jonjic N: VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. International journal of surgical pathology. 2006, 14: 49-55. 10.1177/106689690601400109.CrossRefPubMed
18.
Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Yamashita H, Fukada M: Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer. 2003, 10: 120-128. 10.1007/BF02967636.CrossRefPubMed
19.
Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ: Serum vascular endothelial growth factor in breast cancer. Anticancer Res. 2007, 27: 3481-3487.PubMed
20.
Coskun U, Gunel N, Sancak B, Onuk E, Bayram O, Yilmaz E, Candan S, Ozkan S: Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients. Breast. 2003, 12: 104-110. 10.1016/S0960-9776(02)00214-X.CrossRefPubMed
21.
The Million Women Study: design and characteristics of the study population. The Million Women Study Collaborative Group. Breast Cancer Res. 1999, 1 (1): 73-80. 10.1186/bcr16.
22.
George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res. 2000, 6 (8): 3147-52.PubMed
23.
Ugurel S, Rappl G, Tilgen W, Reinhold U: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001, 19 (2): 577-83.PubMed
24.
Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer. 2001, 92 (3): 663-9. 10.1002/1097-0142(20010801)92:3<663::AID-CNCR1368>3.0.CO;2-L.CrossRefPubMed
25.
De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G: Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004, 100 (2): 270-8. 10.1002/cncr.11911.CrossRefPubMed
26.
Hyder SM, Nawaz Z, Chiappetta C, Stancel GM: Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histol Histopathol. 2000, 15 (1): 325-34.PubMed
27.
Sancak B, Coskun U, Gunel N, Onuk E, Cihan A, Karamercan A, Yildirim Y, Ozkan S: No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery. Internal medicine journal. 2004, 34: 310-315. 10.1111/j.1444-0903.2004.00591.x.CrossRefPubMed
28.
Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A: Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998, 80 (1): 171-5.PubMed
29.
Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF: In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol. 1998, 275 (3 Pt 2): H1054-61.PubMed
30.
Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY: Blood platelets and serum VEGF in cancer patients. Br J Cancer. 1999, 79 (2): 370-3. 10.1038/sj.bjc.6690051.CrossRefPubMed
31.
Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J, Jacobs HS: Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril. 2000, 73: 56-60. 10.1016/S0015-0282(99)00476-8.CrossRefPubMed
32.
Coskun U, Gunel N, Sancak B, Onuk E, Bayram M, Cihan A: Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients. Clinical and experimental immunology. 2004, 137: 546-551. 10.1111/j.1365-2249.2004.02579.x.CrossRefPubMedPubMedCentral
33.
Shibuya M: Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006, 9 (4): 225-30. 10.1007/s10456-006-9055-8. discussion 31CrossRefPubMed
34.
Hyder SM, Nawaz Z, Chiappetta C, Stancel GM: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 60 (12): 3183-90. 2000 Jun 15
Metadata
Title
The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer
Authors
Aoife J Lowery
Karl J Sweeney
Alan P Molloy
Emer Hennessy
Catherine Curran
Michael J Kerin
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-279

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity

Research article

A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

Research article

Loss of Endocan tumorigenic properties after alternative splicing of exon 2

Research article

Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum albumas complimentary therapy in cancer

Research article

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells

Research article

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits